Rare Case of Severe Pancreatitis induced by Encorafenib and Cetuximab in BRAF V600E-Positive Colorectal Cancer

Yu Miyakawa; Yuki Ishigaki; Nobumi Suzuki; Go Endo; Chisaki Suzumori; Takeshi Hayashi; Kenji Tamada; Takuma Iwata; Gota Fujisawa; Yoku Hayakawa; Narikazu Boku; Mitsuhiro Fujishiro

doi:10.2169/internalmedicine.5389-25

Yu Miyakawa, Yuki Ishigaki, Nobumi Suzuki, Go Endo, Chisaki Suzumori, Takeshi Hayashi, Kenji Tamada, Takuma Iwata, Gota Fujisawa, Yoku Hayakawa, Narikazu Boku, Mitsuhiro Fujishiro

Author information

Yu Miyakawa
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
Yuki Ishigaki
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
Nobumi Suzuki
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
Go Endo
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
Chisaki Suzumori
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
Takeshi Hayashi
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
Kenji Tamada
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
Takuma Iwata
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
Gota Fujisawa
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
Yoku Hayakawa
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
Narikazu Boku
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medicine Science, University of Tokyo, Japan
Mitsuhiro Fujishiro
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan

Keywords: BRAF V600E, BEACON, Encorafenib, Cetuximab, Pancreatitis

JOURNAL OPEN ACCESS Advance online publication

Article ID: 5389-25

DOI https://doi.org/10.2169/internalmedicine.5389-25

Details

Abstract

Doublet chemotherapy with encorafenib and cetuximab has demonstrated a survival benefit for BRAF V600E mutation-positive advanced colorectal cancer, which generally has a poor prognosis, as shown in the BEACON CRC trial. We encountered a case of rectal cancer with this mutation, complicated by grade 3 pancreatitis, one month after starting this doublet therapy. Despite aggressive treatment efforts, the pancreatitis led to duodenal ulcer perforation and a fatal intra-abdominal abscess. This case highlights pancreatitis as a rare, but severe, side effect of combination chemotherapy.

Corresponding author

Register with J-STAGE for free!